Limits...
Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study.

Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H - Hepat Mon (2012)

Bottom Line: However, the majority of these have reported a variety of rates, depending on their study population, which limits the generalizability of their results to the general population.Prevalence of HBsAg increased significantly with age (P value < 0.001), but this was not true for HCVAb (P value: 0.67).Prevalence of HCVAb did not differ with respect to any of the potential risk factors.

View Article: PubMed Central - PubMed

Affiliation: Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran.

ABSTRACT

Background: There have been studies regarding the prevalence of hepatitis B surface antigen (HBsAg) and anti-hepatitis C antibody (HCVAb) in Iran. However, the majority of these have reported a variety of rates, depending on their study population, which limits the generalizability of their results to the general population. On the other hand, cultural diversity in the different provinces of Iran also necessitates the performing separate population-based studies in the various regions.

Objectives: To evaluate the population-based prevalence of HBsAg and HCVAb and their correlates in Zahedan City, Iran.

Patients and methods: Included in this study were 2587 individuals, using a random and cluster sampling approach. The participants were drawn from the Family Registry of the public health centers in Zahedan City, Iran, from 2008 to 2009. Following data collection from the interviews, subjects were assessed for seropositivity of HBsAg and HCVAb. We then calculated the prevalence of HBsAg and HCVAb, and evaluated these viral markers for an association with; age, sex and potential risk factors.

Results: Weighted seroprevalence of HBsAg and HCVAb was 2.5% (CI 95% : 1.9 to 3.3 %) and 0.5% (CI 95% : 0.27 to 0.9 %), respectively. Prevalence of HBsAg increased significantly with age (P value < 0.001), but this was not true for HCVAb (P value: 0.67). We observed no sex dominance in the prevalence of HBsAg (3.2% and 2.2% for males and females, respectively, P value: 0.15) or HCVAb (0.4% and 0.7% for males and females, respectively, P value: 0.27). In a multivariate regression analysis, every additional year in age resulted in a 2% increment in the odds of HBsAg seropositivity. HBsAg was also three times more prevalent among married, than single subjects (with a P value reaching toward significance: 0.065) in multivariate analysis. Prevalence of HCVAb did not differ with respect to any of the potential risk factors.

Conclusions: This is the first population-based study on the prevalence of HCVAb and one of the few population based studies on HBsAg in Zahedan City. We detected lower prevalence rates of HBsAg and HCVAb than in previous studies conducted in Zahedan City. In addition to improvements in social awareness and general health elements, we think that the observed low prevalence rates have been achieved due to the efficiency of mass vaccination projects, implemented against HBV infection in Iran.

No MeSH data available.


Related in: MedlinePlus

Age-Specific Prevalence of Hepatitis B Surface Antigens
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3475139&req=5

fig381: Age-Specific Prevalence of Hepatitis B Surface Antigens

Mentions: The overall weighted seroprevalence of HBsAg and HCVAb were 2.5% (CI 95% : 1.9 to 3.3%) and 0.5% (CI 95% : 0.27 to 0.9%), respectively. Although the crude seroprevalence of HBsAg was higher in the males (3.2%) than females (2.2%), however, this difference did not reach statistical significance in proportional analysis (P value, 0.15, Table 2). Moreover, we did not find any significant gender preponderance in the prevalence of HCVAb (P value, 0.273, Table 2) between males (0.4%) and females (0.7%). Table 3 shows the age-specified seroprevalence of HBsAg and HCVAb. Overall and gender specified crude prevalence of HBsAg were linearly associated with age groups (Table 2 and 3, Figure 1). The highest prevalence of HBsAg was observed among subjects over 65 years old. Regarding HCVAb, we did not detect any significant difference among the separate age groups (Table 2 and 3, Figure 2). Due to the low prevalence of HCVAb, we did not perform any age-specified prevalence analysis in separate male and female groups. The prevalence of concomitant HBsAg and HCVAb seropositivity was zero.


Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study.

Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H - Hepat Mon (2012)

Age-Specific Prevalence of Hepatitis B Surface Antigens
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3475139&req=5

fig381: Age-Specific Prevalence of Hepatitis B Surface Antigens
Mentions: The overall weighted seroprevalence of HBsAg and HCVAb were 2.5% (CI 95% : 1.9 to 3.3%) and 0.5% (CI 95% : 0.27 to 0.9%), respectively. Although the crude seroprevalence of HBsAg was higher in the males (3.2%) than females (2.2%), however, this difference did not reach statistical significance in proportional analysis (P value, 0.15, Table 2). Moreover, we did not find any significant gender preponderance in the prevalence of HCVAb (P value, 0.273, Table 2) between males (0.4%) and females (0.7%). Table 3 shows the age-specified seroprevalence of HBsAg and HCVAb. Overall and gender specified crude prevalence of HBsAg were linearly associated with age groups (Table 2 and 3, Figure 1). The highest prevalence of HBsAg was observed among subjects over 65 years old. Regarding HCVAb, we did not detect any significant difference among the separate age groups (Table 2 and 3, Figure 2). Due to the low prevalence of HCVAb, we did not perform any age-specified prevalence analysis in separate male and female groups. The prevalence of concomitant HBsAg and HCVAb seropositivity was zero.

Bottom Line: However, the majority of these have reported a variety of rates, depending on their study population, which limits the generalizability of their results to the general population.Prevalence of HBsAg increased significantly with age (P value < 0.001), but this was not true for HCVAb (P value: 0.67).Prevalence of HCVAb did not differ with respect to any of the potential risk factors.

View Article: PubMed Central - PubMed

Affiliation: Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran.

ABSTRACT

Background: There have been studies regarding the prevalence of hepatitis B surface antigen (HBsAg) and anti-hepatitis C antibody (HCVAb) in Iran. However, the majority of these have reported a variety of rates, depending on their study population, which limits the generalizability of their results to the general population. On the other hand, cultural diversity in the different provinces of Iran also necessitates the performing separate population-based studies in the various regions.

Objectives: To evaluate the population-based prevalence of HBsAg and HCVAb and their correlates in Zahedan City, Iran.

Patients and methods: Included in this study were 2587 individuals, using a random and cluster sampling approach. The participants were drawn from the Family Registry of the public health centers in Zahedan City, Iran, from 2008 to 2009. Following data collection from the interviews, subjects were assessed for seropositivity of HBsAg and HCVAb. We then calculated the prevalence of HBsAg and HCVAb, and evaluated these viral markers for an association with; age, sex and potential risk factors.

Results: Weighted seroprevalence of HBsAg and HCVAb was 2.5% (CI 95% : 1.9 to 3.3 %) and 0.5% (CI 95% : 0.27 to 0.9 %), respectively. Prevalence of HBsAg increased significantly with age (P value < 0.001), but this was not true for HCVAb (P value: 0.67). We observed no sex dominance in the prevalence of HBsAg (3.2% and 2.2% for males and females, respectively, P value: 0.15) or HCVAb (0.4% and 0.7% for males and females, respectively, P value: 0.27). In a multivariate regression analysis, every additional year in age resulted in a 2% increment in the odds of HBsAg seropositivity. HBsAg was also three times more prevalent among married, than single subjects (with a P value reaching toward significance: 0.065) in multivariate analysis. Prevalence of HCVAb did not differ with respect to any of the potential risk factors.

Conclusions: This is the first population-based study on the prevalence of HCVAb and one of the few population based studies on HBsAg in Zahedan City. We detected lower prevalence rates of HBsAg and HCVAb than in previous studies conducted in Zahedan City. In addition to improvements in social awareness and general health elements, we think that the observed low prevalence rates have been achieved due to the efficiency of mass vaccination projects, implemented against HBV infection in Iran.

No MeSH data available.


Related in: MedlinePlus